A Phase 2 Study of AZD2171 in Patients With Recurrent Ovarian, Primary Peritoneal Serous or Fallopian Tube Cancer

Trial ID # NCT00275028
Phase II
Drug Class Angiogenesis Inhibitors: VEGFR
Drug Name Cediranib
Alternate Drug Names Recentin, Cediranib maleate, AZD2171
Drugs in Trial Cediranib
Eligible Participant

Recurrent measurable disease, ≤ 2 prior lines of therapy for recurrence

Patients Enrolled

46; median 2 prior therapies (1-3); 16 Pt-S, 30 Pt-R

Therapy Setting


Study Design

Open-Label, Non-randomized


ORR, DCR, PFS, OS, evaluated per RECIST or CA125


ORR: 17% (8PR, n=46)
DCR: 30% (8PR, 6SD, n=46)
PFS: 5.2 months
OS: NR (median follow up 10.7 months)

Exploratory analysis Pt status:
Pt-S (n=16): ORR: 13% (2PR); DCR: 25% (2PR, 2SD); PFS: 5.2 months
Pt-R (n=30): ORR: 20% (6PR); DCR: 33% (6PR, 4SD); PFS: 5.2 months

Clinically Significant Adverse Events

Serious AE: CNS hemorrhage, dehydration (1 patient)
Grade 3-4 AE: hypertension (46%), fatigue (24%), diarrhea (13%)


Promising activity with significant toxicity (hypertension)


Matulonis UA et al. Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer. J Clin Oncol (2009) 27(33):5601-6

Contact Us
Contact Us

We are here to help! Send us a message below or give us a call at (858) 657-0282.